APP
TEVA icon

Avantax Planning Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Avantax Planning Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-861
Closed -$19K – 1097
2018
Q3 		$19K Buy
+861
New +$20K ﹤0.01% 722
2018
Q2 		– Sell
-861
Closed -$15K – 1343
2018
Q1 		$15K Buy
+861
New +$16.8K ﹤0.01% 900

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Avantax Planning Partners's TEVA Position: Q4 2018 in Review

Avantax Planning Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2018, closing a stake of 861 shares — an estimated $19K sold.

Avantax Planning Partners first reported a position in TEVA in Q1 2018 and held it in 2 quarters. The position peaked at $19K in Q3 2018. 552 funds tracked by Wall St. Rank hold TEVA as of Q4 2018.

  • Avantax Planning Partners reported no remaining Teva Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 861 Teva Pharmaceuticals shares in Q4 2018, an estimated $19K.
  • Avantax Planning Partners first reported a position in Teva Pharmaceuticals in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Teva Pharmaceuticals position peaked at $19K in Q3 2018.
  • 552 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.